Hints and tips:
Showing results for OTSUKA PHARMACEUTCIAL CO LTD
...Otsuka is a subsidiary of Otsuka Holdings, which had group sales of roughly $11bn last year. Silicon Valley-based Proteus Health is privately held and investors include Swiss drugmaker Novartis....
...This month the US Food and Drug Administration gave the green light to Otsuka Pharmaceutical to market a version of its antipsychotic drug Abilify that has an ingestible sensor embedded in the tablet....
...“We have customers in their 60s to young people in the 20s,” says Yusuke Otsuka, chief operating officer at Coincheck, a bitcoin exchange based in Tokyo, who adds that there has been a large increase in...
...Nomura, Morgan Stanley and Goldman Sachs are joint global co-ordinators for the Japan Display offering....
...Important Japanese companies so far absent from the new fund include Otsuka, which is conducting advanced tests on the use of a new drug for tuberculosis....
...Lundbeck, the Danish drug developer, climbed 8.9 per cent to DKr108 after its Japanese partner Otsuka Holdings said it was to pay as much as $825m for an experimental Alzheimer’s treatment....
...Curriculum vitae: Akio Otsuka Born: 1953 Education 1976: Kyoto University, faculty of law Career 1976: Joined Sumitomo Trust & Banking Co 1998: Sumitomo Trust & Banking Co, general manager of pension...
...Nexon’s IPO, Japan’s biggest since drugmaker Otsuka Holdings raised Y160bn last year, came in an unsettled market, with the benchmark Nikkei index down about 17 per cent in the year to date....
...In one of Japan’s biggest IPOs this year, Otsuka sold a total of Y198.5bn ($2.4bn) worth of shares, including the greenshoe option, at Y2,100 – the lower end of its price range....
...Otsuka is best known for Ablify, which is marketed by Bristol-Myers Squibb in the US. Credit Suisse estimates that US sales alone of the drug contributed Y320bn to Otsuka’s revenues....
...Otsuka, the pharmaceuticals group, made a positive market debut. The company’s shares closed at Y2,140, up 1.9 per cent from its initial public offering price....
International Edition